← Back to patent-cliff list
Sitagliptin Tartrate
Tier C — Watch / tradeSitagliptin Tartrate
Heumann Pharma GmbH & Co Generica KG
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DPP4
Brand：Sitagliptin Heumann 25 mg Filmtabletten
Indications (approved)：Non-alcoholic steatohepatitis, Diabetic nephropathy, Type 1 diabetes, Parkinson's disease
Regional status
US
-
EU
Approved
2020-12-14
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sitagliptin Tartrate?
Approved indications include: Non-alcoholic steatohepatitis, Diabetic nephropathy, Type 1 diabetes, Parkinson's disease.
When does the Sitagliptin Tartrate patent expire?
No public expiry year is available for Sitagliptin Tartrate yet; this page updates once verified.
How do I get a quote for Sitagliptin Tartrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27